Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is a promising biopharmaceutical company with a diversified product portfolio, including BRUKINSA and sonrotoclax, targeting multiple mechanisms of action in oncology. The company's recent Q1 results show strong revenue growth and a beat in revenue and earnings estimates, leading to an increased FY26 guidance. Upcoming catalysts such as the potential approval of sonrotoclax and updates on solid tumor programs, including the GPC3 x 4-1BB bsAb, could contribute significantly to future revenues. However, there are risks related to R&D, regulatory, and commercial setbacks that could affect the company's success. Overall, the company's strong position in the CLL market and potential for long-term value creation make it a buy.

Bears say

BeOne Medicines is currently operating at a loss due to their numerous ongoing trials and relatively high research and development expenses, with a potential filing for BTK-CDAC in 2H26 and initial data for several other programs not expected until 2026. Additionally, the company has deprioritized several early-stage programs based on early data, and while their BTK-CDAC could potentially generate significant revenue in the near-term, it may not be enough to offset their current losses. As a result, financial analysts have a negative outlook on BeOne Medicines' stock.

BeiGene Ltd (ONC) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 12 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of May 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $386.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $386.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.